PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Toward a Genomic understanding of Multiple Myeloma

Sponsor
MMRC

Protocol Number
MMRC Genomic Tissue Collection

To Learn More Call
201-510-0910

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Sponsor
Celgene

Protocol Number
Celgene ABI-007-ST-001

To Learn More Call
201-510-0910

Phase Ib-IIA study of combined check point inhibition after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 001 (CA209-694)

To Learn More Call
201-510-0910

A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

Sponsor
GOG

Protocol Number
GOG-0274

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
RTOG

Protocol Number
RTOG 0724 / GOG-0724

To Learn More Call
201-510-0910

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-4047-MM-014

To Learn More Call
201-510-0910

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Part A)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Polynoma

Protocol Number
103A-301

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308